EQRx, Inc.
EQRXDelisted Nov 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001843762
EQRx, Inc. was delisted on Nov 9, 2023; its insiders filed their last Form 4 on Nov 14, 2023; 132 institutions reported holding it in 13F filings for Q3 2023, worth $768.6M in total; no superinvestor held it.
Holders of 5% or more of EQRX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of EQRx, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of EQRx, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
7 Schedule 13D and 13G filings on EQRx, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 2022 | GV 2019, L.P. | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Citadel Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | ARCH Venture Fund X, L.P. | 13GOld format | – | New | – | SEC |
| Dec 30, 2021 | Casdin Eli | 13DOld format | – | New | – | SEC |
| Dec 27, 2021 | AH Bio Fund II, L.P. | 13DOld format | – | New | – | SEC |
| Dec 27, 2021 | SB Management Ltd | 13DOld format | – | New | – | SEC |
| Dec 10, 2021 | Citadel Advisors LLC | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell EQRx, Inc. shares.
No Form 144 notices for EQRx, Inc. are on file.